Therapeutic intratumoral (i.t.)treatment of established melanomas on day 7 with artLCMV-TRP2 led to tumor regression in all mice with long-term cure in ~60% of the mice, in a dose-independent manner (Fig. 1b, c, Supplementary Fig. 1a). Here, DCT is linked to neoplasm.